Sutro Biopharma, Inc. cash flow to debt ratio of -1.13K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sutro Biopharma, Inc.'s free cash flow has increased -8.07% from $-194.64M last year to $-178.93M, signaling increasing performance

Sutro Biopharma, Inc.'s debt to equity ratio is -0.20, signaling that the company spent its equity and risk bankruptcy.

Sutro Biopharma, Inc.'s debt to equity ratio is -0.20, signaling that the company spent its equity and risk bankruptcy.

Sutro Biopharma, Inc. has negative EBITDA, making leverage ratio unreliable

Sutro Biopharma, Inc.'s interest coverage ratio is -2.89, which means that the company struggles to meet interest obligations, signaling financial risk.

Sutro Biopharma, Inc.'s profit margin has increased (-57.94%) in the last year from -366.62% to -154.21%, signaling increasing performance

Sutro Biopharma, Inc.'s short-term assets of $150.93M exceed its short-term liabilities of $75.13M

Sutro Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sutro Biopharma, Inc.'s return on equity of 192.77%, is higher than 15.00%, indicating good performance

Sutro Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sutro Biopharma, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Sutro Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sutro Biopharma, Inc. has negative free cash flow, indicating cash burn

Sutro Biopharma, Inc.'s yearly earnings has increased -15.99% since last year from $-227.46M to $-191.09M, signaling increasing performance

Sutro Biopharma, Inc.'s yearly revenue has increased 65.18% since last year from $62.04M to $102.48M, signaling increasing performance

ROIC -64.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sutro Biopharma, Inc.'s 3-year revenue CAGR of 14.78% is positive, indicating growing revenue over the past 3 years

Sutro Biopharma, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Sutro Biopharma, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Sutro Biopharma, Inc. has insufficient data to evaluate this check.

Sutro Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sutro Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sutro Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sutro Biopharma, Inc. is overvalued relative to its fair value price of -371.65 based on Earnings Fair Value model

Sutro Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sutro Biopharma, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Sutro Biopharma, Inc. has a price-to-sales ratio of 0.03x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue